Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

INTRODUCTION: Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Ther
Main Authors: Nash, Peter, McInnes, Iain B., Mease, Philip J., Thom, Howard, Hunger, Matthias, Karabis, Andreas, Gandhi, Kunal, Mpofu, Shephard, Jugl, Steffen M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935619/
https://ncbi.nlm.nih.gov/pubmed/29605841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-018-0106-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados